Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancer

BMC Immunology

Volumn 11, Issue , 2010, Pages

  Hu, Zhiwei ^a,b   Li, Jing ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR 7; CHIMERIC ANTIBODY; ICON; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOMODULATING AGENT; UNCLASSIFIED DRUG; HYBRID PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL ACTIVITY; CELL FUNCTION; CELL ISOLATION; CELL KILLING; CHO CELL; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; SEVERE COMBINED IMMUNODEFICIENCY; SQUAMOUS CELL CARCINOMA; TONGUE CANCER; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; COMPLEMENT ACTIVATION; CYTOTOXICITY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; MOUSE MUTANT; PATHOLOGY; TONGUE TUMOR; TUMOR CELL LINE;

ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; COMPLEMENT ACTIVATION; CYTOTOXICITY, IMMUNOLOGIC; FACTOR VII; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; TONGUE NEOPLASMS;

EID: 77957724772     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-11-49     Document Type: Article

References (57)

1. Alessi P, Ebbinghaus C, Neri D. Molecular targeting of angiogenesis. Biochim Biophys Acta 2004, 1654:39-49.
2. Folkman J. Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther 2003, 2:S127-33.
3. Patterson DM, Rustin GJ. Vascular damaging agents. Clin Oncol (R Coll Radiol) 2007, 19:443-56.
4. Pilat MJ, Lorusso PM. Vascular disrupting agents. J Cell Biochem 2006, 99:1021-39. 10.1002/jcb.20783, 16927308.
5. Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marme D, Lorusso PM. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005, 11:416-20.
6. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004, 10:415-27. 10.1158/1078-0432.CCR-0642-03, 14760060.
7. Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006, 66:11520-39. 10.1158/0008-5472.CAN-06-2848, 17178843.
8. Hu Z, Sun Y, Garen A. Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Proc Natl Acad Sci USA 1999, 96:8161-6. 10.1073/pnas.96.14.8161, 22205, 10393965.
9. Hu Z, Garen A. Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy. Proc Natl Acad Sci USA 2000, 97:9221-5. 10.1073/pnas.97.16.9221, 16849, 10922073.
10. Hu Z, Garen A. Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. Proc Natl Acad Sci USA 2001, 98:12180-5. 10.1073/pnas.201420298, 59788, 11593034.
11. Morrissey JH, Fakhrai H, Edgington TS. Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell 1987, 50:129-35. 10.1016/0092-8674(87)90669-6, 3297348.
12. Spicer EK, Horton R, Bloem L, Bach R, Williams KR, Guha A, Kraus J, Lin TC, Nemerson Y, Konigsberg WH. Isolation of cDNA clones coding for human tissue factor: primary structure of the protein and cDNA. Proc Natl Acad Sci USA 1987, 84:5148-52. 10.1073/pnas.84.15.5148, 298811, 3037536.
13. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996, 2:209-15. 10.1038/nm0296-209, 8574967.
14. Shoji M, Hancock WW, Abe K, Micko C, Casper KA, Baine RM, Wilcox JN, Danave I, Dillehay DL, Matthews E, et al. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998, 152:399-411. 1857968, 9466566.
15. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995, 146:1029-39. 1869291, 7538264.
16. Zucker S, Mirza H, Conner CE, Lorenz AF, Drews MH, Bahou WF, Jesty J. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer 1998, 75:780-6. 10.1002/(SICI)1097-0215(19980302)75:5<780::AID-IJC19>3.0.CO;2-A, 9495249.
17. Osterud B. Tissue factor: a complex biological role. Thromb Haemost 1997, 78:755-8.
18. Semeraro N, Colucci M. Tissue factor in health and disease. Thromb Haemost 1997, 78:759-64.
19. Rao LV, Pendurthi UR. Tissue factor on cells. Blood Coagul Fibrinolysis 1998, 9(1):S27-35.
20. Mulder AB, Blom NR, Smit JW, Ruiters MH, van der Meer J, Halie MR, Bom VJ. Basal tissue factor expression in endothelial cell cultures is caused by contaminating smooth muscle cells. Reduction by using chymotrypsin instead of collagenase. Thromb Res 1995, 80:399-411. 10.1016/0049-3848(95)00192-T, 8588201.
21. Waxman E, Ross JB, Laue TM, Guha A, Thiruvikraman SV, Lin TC, Konigsberg WH, Nemerson Y. Tissue factor and its extracellular soluble domain: the relationship between intermolecular association with factor VIIa and enzymatic activity of the complex. Biochemistry 1992, 31:3998-4003. 10.1021/bi00131a015, 1567850.
22. Presta L, Sims P, Meng YG, Moran P, Bullens S, Bunting S, Schoenfeld J, Lowe D, Lai J, Rancatore P, et al. Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic. Thromb Haemost 2001, 85:379-89.
23. Tang Y, Borgstrom P, Maynard J, Koziol J, Hu Z, Garen A, Deisseroth A. Mapping of angiogenic markers for targeting of vectors to tumor vascular endothelial cells. Cancer Gene Ther 2007, 14:346-53. 10.1038/sj.cgt.7701030, 17235351.
24. Bora PS, Hu Z, Tezel TH, Sohn JH, Kang SG, Cruz JM, Bora NS, Garen A, Kaplan HJ. Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration. Proc Natl Acad Sci USA 2003, 100:2679-84. 10.1073/pnas.0438014100, 151400, 12589025.
25. Tezel TH, Bodek E, Sonmez K, Kaliappan S, Kaplan HJ, Hu Z, Garen A. Targeting tissue factor for immunotherapy of choroidal neovascularization by intravitreal delivery of factor VII-Fc chimeric antibody. Ocul Immunol Inflamm 2007, 15:3-10. 10.1080/09273940601147760, 17365800.
26. Krikun G, Hu Z, Osteen K, Bruner-Tran KL, Schatz F, Taylor HS, Toti P, Arcuri F, Konigsberg W, Garen A, et al. The immunoconjugate "icon" targets aberrantly expressed endothelial tissue factor causing regression of endometriosis. Am J Pathol 2010, 176:1050-6. 10.2353/ajpath.2010.090757, 20042667.
27. Cocco E, Hu Z, Richter CE, Bellone S, Casagrande F, Bellone M, Todeschini P, Krikun G, Silasi DA, Azodi M, et al. hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. Br J Cancer 2010, 103:812-9. 10.1038/sj.bjc.6605760, 20700124.
28. Xu XQ. [Chromosome study on the Tca8113 cell line derived from squamous cell carcinoma of the human tongue]. Zhonghua Zhong Liu Za Zhi 1986, 8:112-4.
29. Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. Nature 1983, 301:527-30. 10.1038/301527a0, 6823332.
30. Dorshkind K, Pollack SB, Bosma MJ, Phillips RA. Natural killer (NK) cells are present in mice with severe combined immunodeficiency (scid). J Immunol 1985, 134:3798-801.
31. Roder J, Duwe A. The beige mutation in the mouse selectively impairs natural killer cell function. Nature 1979, 278:451-3. 10.1038/278451a0, 313007.
32. MacDougall JR, Croy BA, Chapeau C, Clark DA. Demonstration of a splenic cytotoxic effector cell in mice of genotype SCID/SCID.BG/BG. Cell Immunol 1990, 130:106-17. 10.1016/0008-8749(90)90165-N, 2144467.
33. Arase H, Saito T, Phillips JH, Lanier LL. Cutting edge: the mouse NK cell-associated antigen recognized by DX5 monoclonal antibody is CD49b (alpha 2 integrin, very late antigen-2). J Immunol 2001, 167:1141-4.
34. Fischer MB, Ma M, Goerg S, Zhou X, Xia J, Finco O, Han S, Kelsoe G, Howard RG, Rothstein TL, et al. Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol 1996, 157:549-56.
35. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992, 89:4285-9. 10.1073/pnas.89.10.4285, 49066, 1350088.
36. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-45.
37. Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, Touge H, Makino H, Takata M, Miyata M, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007, 13:1552-61. 10.1158/1078-0432.CCR-06-1726, 17332301.
38. Herberman RB, Djeu J, Kay HD, Ortaldo JR, Riccardi C, Bonnard GD, Holden HT, Fagnani R, Santoni A, Puccetti P. Natural killer cells: characteristics and regulation of activity. Immunol Rev 1979, 44:43-70. 10.1111/j.1600-065X.1979.tb00267.x, 761939.
39. Varker KA, Terrell CE, Welt M, Suleiman S, Thornton L, Andersen BL, Carson WE. Impaired natural killer cell lysis in breast cancer patients with high levels of psychological stress is associated with altered expression of killer immunoglobin-like receptors. J Surg Res 2007, 139:36-44. 10.1016/j.jss.2006.08.037, 1932802, 17292412.
40. Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, Matsumoto Y. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res 2002, 62:5813-7.
41. Kawaguchi Y, Kono K, Mimura K, Mitsui F, Sugai H, Akaike H, Fujii H. Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer 2007, 97:494-501. 10.1038/sj.bjc.6603885, 2360355, 17622245.
42. Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2007, 120:781-7. 10.1002/ijc.22370, 17096332.
43. Ratliff TL, McCool RE, Catalona WJ. Antibody-dependent and spontaneous lympholysis in urologic cancer patients. Br J Cancer 1979, 39:667-75. 2009983, 444405.
44. Platsoucas CD, Fernandes G, Gupta SL, Kempin S, Clarkson B, Good RA, Gupta S. Defective spontaneous and antibody-dependent cytotoxicity mediated by E-rosette-positive and E-rosette-negative cells in untreated patients with chronic lymphocytic leukemia: augmentation by in vitro treatment with interferon. J Immunol 1980, 125:1216-23.
45. Ziegler HW, Kay NE, Zarling JM. Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer 1981, 27:321-7. 10.1002/ijc.2910270310, 6169660.
46. Kay NE, Zarling JM. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood 1984, 63:305-9.
47. Matsuzaki H, Kagimoto T, Oda T, Kawano F, Takatsuki K. Natural killer activity and antibody-dependent cell-mediated cytotoxicity in multiple myeloma. Jpn J Clin Oncol 1985, 15:611-7.
48. Albright JW, Albright JF. Age-associated impairment of murine natural killer activity. Proc Natl Acad Sci USA 1983, 80:6371-5. 10.1073/pnas.80.20.6371, 394299, 6604919.
49. Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006, 8:215. 10.1186/bcr1612, 1797036, 17096862.
50. Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, Silva LS, Villani L, Tagliabue E, Menard S, et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 2007, 67:11991-9. 10.1158/0008-5472.CAN-07-2068, 18089830.
51. Lister J, Rybka WB, Donnenberg AD, deMagalhaes-Silverman M, Pincus SM, Bloom EJ, Elder EM, Ball ED, Whiteside TL. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period. Clin Cancer Res 1995, 1:607-14.
52. deMagalhaes-Silverman M, Donnenberg A, Lembersky B, Elder E, Lister J, Rybka W, Whiteside T, Ball E. Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer. J Immunother 2000, 23:154-60. 10.1097/00002371-200001000-00018, 10687148.
53. Bachanova V, Burns LJ, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lindgren BR, Cooley S, Weisdorf D, Miller JS. Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother 2010, 59:1739-44. 10.1007/s00262-010-0896-z, 20680271.
54. Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, Baselga J, Caligiuri MA. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 2001, 31:3016-25. 10.1002/1521-4141(2001010)31:10<3016::AID-IMMU3016>3.0.CO;2-J, 11592078.
55. Berkner KL. Expression of recombinant vitamin K-dependent proteins in mammalian cells: factors IX and VII. Methods Enzymol 1993, 222:450-77. full_text, 8412810.
56. Nyberg-Hoffman C, Aguilar-Cordova E. Instability of adenoviral vectors during transport and its implication for clinical studies. Nat Med 1999, 5:955-7. 10.1038/11400, 10426323.
57. Walford RL, Gallagher R, Sjaarda JR. Serologic Typing of Human Lymphocytes with Immune Serum Obtained after Homografting. Science 1964, 144:868-70. 10.1126/science.144.3620.868, 14149404.